03/09/2010 (3:57 pm)
This may be a great time to buy health care stocks
The complex prescription for successful health care investing usually includes the careful consideration of drug pipelines, current-product sales, patent expirations, potential mergers and stock dividends.
Add to that list in 2010 an untested ingredient called health care reform.
"Institutional investors don’t want to see big headlines about the health care industry that they weren’t able to predict," said Les Funtleyder, health care strategist for Miller Tabak & Co. in New York. "So they’re currently operating on the fear of increased regulation or pricing pressures."
If you’re in any way optimistic that the outcome of health care reform won’t be bad for drug companies, the current fears mean that health care stock prices will never be more reasonable than they are now. Prices are depressed and the dividends solid.
"Once we know what the reform will look like in detail we can then move forward," believes Linda Bannister, health care analyst for Edward Jones in St. Louis. "Managed care is the most at risk from health care reform, and then the risk declines from there."
Beyond the potential negatives of reform on drug stocks there may be some long-term positives.
"If 30 million people who didn’t have health insurance were to have it, imagine what that does for a pharmaceutical company," said James Molloy, pharmaceutical analyst for Caris & Co. in Boston. "The plus side of drugs is that most people with insurance never pay full price, but instead pay a co-pay, and you can imagine what kind of car everyone would drive if they had a co-pay for their gas."
While awaiting a clear prognosis on reform, investors must fall back on traditional considerations that tend to favor big pharma that keeps growing bigger.
Merck & Co., whose stock is flat this year after a 25 percent gain last year, is recommended by Bannister and Funtleyder because its strong product pipeline means it won’t require the endless cutting of costs to be profitable. It faces loss of patents on several key drugs in coming years and fierce competition, yet its financial health is strong and its research excellent.
Merck’s launches of diabetes drug Januvia, papillomavirus vaccine Gardasil and HIV drug Isentress have all been successes, while its acquisition of Schering-Plough could result in $3.5 billion in annual cost-saving synergies by 2012. More than half of Merck’s sales are outside the U.S.
Johnson & Johnson, its stock down slightly this year after last year’s 11 percent rise, has suffered through a period of patent expirations, but Bannister believes its drug pipeline coupled with continued efficiencies should accelerate its growth. It benefits from being the world’s largest and most diverse health-care company, with the top or number-two leadership position in 70 percent of its products.
"I cover mostly smaller names of the world and try to find those with downside protection in the form of some core value," said Molloy.
Warner Chilcott Plc, whose stock is down 8 percent this year after last year’s 96 percent gain, is Molloy’s top pick in part because it has massive cash flow. This marketer of women’s health and dermatology products recently purchased Procter & Gamble’s prescription drug business. Its product mix includes hormonal oral contraceptives and hormone therapy products for menopausal symptoms, as well as topical products for psoriasis and an antibiotic for acne.
The other Molloy favorite is Endo Pharmaceutical Holdings Inc., up 10 percent this year after last year’s 21 percent decline. It is a specialty drug company in pain management whose flagship product is the Lidoderm adhesive patch for post-shingle pain. The company, which cross-sells many of its pain-related products, last year acquired Indevus Pharmaceuticals, which specializes in urology and endocrinology.
"My biggest consideration is whether the good news or bad news is factored into the stock price," explained Molloy. "I also ask whether its primary drug has to be a $1 billion drug for the company’s stock price to go higher."
Novartis AG and Bristol Myers Squibb Co. are Funtleyder’s other favorites. Though he says "no one is firing on all cylinders right now," there is little downside, they offer solid dividends and their upside is the enormous potential of their drug pipelines.
Mergers can come fast and furious among drug companies, but is an unpredictable trend that none of the experts expect will take place soon.
"Pharma has been a consolidating industry ever since it was an industry," said Funtleyder, noting that patent expirations and slowing sales drove the most recent mergers and innovation may someday drive the next go-around. "Consolidation happens in waves and last year was a pretty big wave, so we think there will be a break for a couple of years before we see the next wave of consolidation."
Other Bannister choices include Eli Lilly & Co., Pfizer Inc. and Abbott Laboratories.
"If a company like Lilly is unable to execute its pipeline, then at some point it is going to have to make a sizeable acquisition or it will potentially be acquired," concluded Bannister, who considers investment in Lilly a three- to five-year story. "Yet most of these companies’ strategies are licensing deals or small ‘tuck-in’ acquisitions, so I’m not betting on a new wave of industry consolidation."
Payday loans online from $100 to 1000 loan payday with no faxing. Get cash advance loans now. Click here for immediate funding.